Sequence 19 from Patent US 20060122119

General Information


DRACP ID  DRACP01263

Peptide Name   Sequence 19 from Patent US 20060122119

Sequence  EVDPIGHLY

Sequence Length  9

UniProt ID  P43357  Q4K5A5  C3K2R1  Q3K660  B0KL79 

PubChem CID  Not available

Origin  Homo sapiens

Type  Native peptide

Classification

  

Active ACP



Activity Information


Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Antitumor



Structure Information


PDB ID  Not available

Predicted Structure  DRACP01263

Helicity  Not available

Linear/Cyclic  Not available

Disulfide/Other Bond  Not available

N-terminal Modification  Not available

C-terminal Modification  Not available

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C48H71N11O15

Absent amino acids  ACFKMNQRSTW

Common amino acids  DEGHILPVY

Mass  118504

Pl  4.18

Basic residues  1

Acidic residues  2

Hydrophobic residues  3

Net charge  -1

Boman Index  -551

Hydrophobicity  -11.11

Aliphatic Index  118.89

Half Life 
  Mammalian: 1 hour
  Yeast: 30 min
  E.coli: >10 hour

Extinction Coefficient cystines  1490

Absorbance 280nm  186.25

Polar residues  2

Amino acid distribution



Literature Information


Literature 1

Pubmed ID Not available

Title  Not available

Doi Not available

Year  Not available

Patent

Patent ID US 2006/0122119 A1

Patent Title  Peptides for use in antitumor immunotherapy.

Other Iinformation  Granted Patent Family: 10s / 10ex; Family Jurisdictions: CA, AU, FR, WO, US, EP, JP; Legal Status: Discontinued; Application No: 50633405; Filed:May 25, 2005; Published: Jun 8, 2006; Earliest Priority: Mar 4, 2002

Other Published ID  CA2477762A1  EP1481009A2  WO2003074565A2  WO2003074565A3 




DRACP is developed by Dr.Zheng's team.